{"id":18198,"date":"2025-01-10T12:25:56","date_gmt":"2025-01-10T17:25:56","guid":{"rendered":"https:\/\/sosv.com\/?p=18198"},"modified":"2025-09-09T17:30:37","modified_gmt":"2025-09-09T21:30:37","slug":"rybodyn-discovers-cryptic-human-proteome-secures-4m-for-novel-cancer-immunotherapy-advancements","status":"publish","type":"post","link":"https:\/\/sosv.com\/rybodyn-discovers-cryptic-human-proteome-secures-4m-for-novel-cancer-immunotherapy-advancements\/","title":{"rendered":"Rybodyn Discovers Cryptic Human Proteome, Secures $4M for Novel Cancer Immunotherapy Advancements"},"content":{"rendered":"\n

Rybodyn, Inc.<\/a> is making waves in biotech with its groundbreaking discovery of a cryptic human proteome and a $4 million pre-seed funding round. A 2024 graduate of SOSV\u2019s IndieBio SF<\/a>, Rybodyn is targeting the dark proteome to pioneer first-in-class immunotherapies for cancer – with the potential to address a wide range of other diseases as well.<\/p>\n\n\n\n

At the heart of Rybodyn\u2019s breakthrough is RyboCypher\u2122, a proprietary RNA sequencing technology that identifies RNA molecules previously overlooked by next-generation sequencing methods. Already, RyboCypher\u2122 has uncovered thousands of previously unrecognized protein fragments, or peptides, on cell surfaces. Of the over 8,000 fragments identified, approximately 1,000 are cancer-cell specific, presenting new opportunities for therapeutic development.<\/p>\n\n\n\n

\u201cWe knew this class of RNA molecules existed in cells before we developed RyboCypher\u2122<\/strong> to observe them at high resolution. What we didn\u2019t realize was how much protein is being produced from them,\u201d says Dr. Corey Dambacher, Co-founder and President of Rybodyn in the company’s recent press release<\/a>. \u201cWe now have a scalable way to find and validate these peptides for making new immunotherapies.”<\/em><\/p>\n\n\n\n

The cryptic human proteome resides in regions of the genome once dismissed as \u201cjunk\u201d DNA. Many of these newly discovered proteins, designated as Dark Targets\u2122<\/strong>, are druggable peptides uniquely expressed on cancer cells, making them ideal for immunotherapy. \u201cWhat sets Rybodyn apart from other dark genome startups is their novel method for visualizing a dark proteome that others can\u2019t see,\u201d <\/em>says Po Bronson, General Partner at SOSV and Managing Director of IndieBio SF.<\/p>\n\n\n\n

The round was co-led by Genedant Capital and SeaX Ventures, with significant participation from SOSV and Swell VC. Rybodyn plans to use the new funding to expand its target discovery and accelerate drug development. Dr. Imad Ajjawi, CEO and co-founder of RyboDyn says, \u201cOur goal is to build a premier pipeline of first-in-class, next-generation immunotherapies, developed both internally and in partnership with large pharmaceutical companies.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"

Rybodyn, Inc. is making waves in biotech with its groundbreaking discovery of a cryptic human proteome and a $4 million pre-seed funding round.<\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":true,"_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","inline_featured_image":false,"footnotes":""},"categories":[1],"tags":[],"tx_company":[2310],"tx_category":[1132,1070,1069],"tx_trend":[2493,30],"tx_program":[1048],"posts_type":[17],"class_list":["post-18198","post","type-post","status-publish","format-standard","hentry","category-uncategorized","tx_company-rybodyn","tx_category-healthcare","tx_category-human-health","tx_category-therapeutics","tx_trend-deep-tech-100","tx_trend-human-health-100","tx_program-indiebio","posts_type-press"],"acf":{"founder_names":"","founder_positions":"","founder_companies":"","founder_spotlight_image":"","publisher":"PRNewswire","author":"","article_url":"https:\/\/www.prnewswire.com\/news-releases\/rybodyn-inc-announces-discovery-of-a-cryptic-human-proteome-and-4m-pre-seed-financing-302346746.html","portal_id":""},"yoast_head":"\nRybodyn Discovers Cryptic Human Proteome, Secures $4M for Novel Cancer Immunotherapy Advancements - SOSV<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/sosv.com\/rybodyn-discovers-cryptic-human-proteome-secures-4m-for-novel-cancer-immunotherapy-advancements\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Rybodyn Discovers Cryptic Human Proteome, Secures $4M for Novel Cancer Immunotherapy Advancements\" \/>\n<meta property=\"og:description\" content=\"Rybodyn, Inc. is making waves in biotech with its groundbreaking discovery of a cryptic human proteome and a $4 million pre-seed funding round.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/sosv.com\/rybodyn-discovers-cryptic-human-proteome-secures-4m-for-novel-cancer-immunotherapy-advancements\/\" \/>\n<meta property=\"og:site_name\" content=\"SOSV\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SOSVvc\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-10T17:25:56+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-09T21:30:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/sosv.com\/wp-content\/uploads\/2024\/12\/1200x627-social-media-2024.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"627\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Ned Desmond\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@sosv\" \/>\n<meta name=\"twitter:site\" content=\"@sosv\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Ned Desmond\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/sosv.com\/rybodyn-discovers-cryptic-human-proteome-secures-4m-for-novel-cancer-immunotherapy-advancements\/\",\"url\":\"https:\/\/sosv.com\/rybodyn-discovers-cryptic-human-proteome-secures-4m-for-novel-cancer-immunotherapy-advancements\/\",\"name\":\"Rybodyn Discovers Cryptic Human Proteome, Secures $4M for Novel Cancer Immunotherapy Advancements - SOSV\",\"isPartOf\":{\"@id\":\"https:\/\/sosv.com\/#website\"},\"datePublished\":\"2025-01-10T17:25:56+00:00\",\"dateModified\":\"2025-09-09T21:30:37+00:00\",\"author\":{\"@id\":\"https:\/\/sosv.com\/#\/schema\/person\/fdcc242b3b857e1d9b7276e662b2bd96\"},\"breadcrumb\":{\"@id\":\"https:\/\/sosv.com\/rybodyn-discovers-cryptic-human-proteome-secures-4m-for-novel-cancer-immunotherapy-advancements\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/sosv.com\/rybodyn-discovers-cryptic-human-proteome-secures-4m-for-novel-cancer-immunotherapy-advancements\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/sosv.com\/rybodyn-discovers-cryptic-human-proteome-secures-4m-for-novel-cancer-immunotherapy-advancements\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/sosv.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Rybodyn Discovers Cryptic Human Proteome, Secures $4M for Novel Cancer Immunotherapy Advancements\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/sosv.com\/#website\",\"url\":\"https:\/\/sosv.com\/\",\"name\":\"SOSV\",\"description\":\"Deep Tech for Human and Planetary Health\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/sosv.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/sosv.com\/#\/schema\/person\/fdcc242b3b857e1d9b7276e662b2bd96\",\"name\":\"Ned Desmond\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/sosv.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/sosv.com\/wp-content\/uploads\/2022\/06\/ned-desmond-profile-2023.jpg\",\"contentUrl\":\"https:\/\/sosv.com\/wp-content\/uploads\/2022\/06\/ned-desmond-profile-2023.jpg\",\"caption\":\"Ned Desmond\"},\"url\":\"https:\/\/sosv.com\/author\/ned\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Rybodyn Discovers Cryptic Human Proteome, Secures $4M for Novel Cancer Immunotherapy Advancements - SOSV","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/sosv.com\/rybodyn-discovers-cryptic-human-proteome-secures-4m-for-novel-cancer-immunotherapy-advancements\/","og_locale":"en_US","og_type":"article","og_title":"Rybodyn Discovers Cryptic Human Proteome, Secures $4M for Novel Cancer Immunotherapy Advancements","og_description":"Rybodyn, Inc. is making waves in biotech with its groundbreaking discovery of a cryptic human proteome and a $4 million pre-seed funding round.","og_url":"https:\/\/sosv.com\/rybodyn-discovers-cryptic-human-proteome-secures-4m-for-novel-cancer-immunotherapy-advancements\/","og_site_name":"SOSV","article_publisher":"https:\/\/www.facebook.com\/SOSVvc\/","article_published_time":"2025-01-10T17:25:56+00:00","article_modified_time":"2025-09-09T21:30:37+00:00","og_image":[{"width":1200,"height":627,"url":"https:\/\/sosv.com\/wp-content\/uploads\/2024\/12\/1200x627-social-media-2024.jpg","type":"image\/jpeg"}],"author":"Ned Desmond","twitter_card":"summary_large_image","twitter_creator":"@sosv","twitter_site":"@sosv","twitter_misc":{"Written by":"Ned Desmond","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/sosv.com\/rybodyn-discovers-cryptic-human-proteome-secures-4m-for-novel-cancer-immunotherapy-advancements\/","url":"https:\/\/sosv.com\/rybodyn-discovers-cryptic-human-proteome-secures-4m-for-novel-cancer-immunotherapy-advancements\/","name":"Rybodyn Discovers Cryptic Human Proteome, Secures $4M for Novel Cancer Immunotherapy Advancements - SOSV","isPartOf":{"@id":"https:\/\/sosv.com\/#website"},"datePublished":"2025-01-10T17:25:56+00:00","dateModified":"2025-09-09T21:30:37+00:00","author":{"@id":"https:\/\/sosv.com\/#\/schema\/person\/fdcc242b3b857e1d9b7276e662b2bd96"},"breadcrumb":{"@id":"https:\/\/sosv.com\/rybodyn-discovers-cryptic-human-proteome-secures-4m-for-novel-cancer-immunotherapy-advancements\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/sosv.com\/rybodyn-discovers-cryptic-human-proteome-secures-4m-for-novel-cancer-immunotherapy-advancements\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/sosv.com\/rybodyn-discovers-cryptic-human-proteome-secures-4m-for-novel-cancer-immunotherapy-advancements\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/sosv.com\/"},{"@type":"ListItem","position":2,"name":"Rybodyn Discovers Cryptic Human Proteome, Secures $4M for Novel Cancer Immunotherapy Advancements"}]},{"@type":"WebSite","@id":"https:\/\/sosv.com\/#website","url":"https:\/\/sosv.com\/","name":"SOSV","description":"Deep Tech for Human and Planetary Health","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/sosv.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/sosv.com\/#\/schema\/person\/fdcc242b3b857e1d9b7276e662b2bd96","name":"Ned Desmond","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/sosv.com\/#\/schema\/person\/image\/","url":"https:\/\/sosv.com\/wp-content\/uploads\/2022\/06\/ned-desmond-profile-2023.jpg","contentUrl":"https:\/\/sosv.com\/wp-content\/uploads\/2022\/06\/ned-desmond-profile-2023.jpg","caption":"Ned Desmond"},"url":"https:\/\/sosv.com\/author\/ned\/"}]}},"featured_image_src":null,"featured_image_src_square":null,"author_info":{"display_name":"Ned Desmond","author_link":"https:\/\/sosv.com\/author\/ned\/"},"_links":{"self":[{"href":"https:\/\/sosv.com\/wp-json\/wp\/v2\/posts\/18198","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sosv.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/sosv.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/sosv.com\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/sosv.com\/wp-json\/wp\/v2\/comments?post=18198"}],"version-history":[{"count":0,"href":"https:\/\/sosv.com\/wp-json\/wp\/v2\/posts\/18198\/revisions"}],"wp:attachment":[{"href":"https:\/\/sosv.com\/wp-json\/wp\/v2\/media?parent=18198"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/sosv.com\/wp-json\/wp\/v2\/categories?post=18198"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/sosv.com\/wp-json\/wp\/v2\/tags?post=18198"},{"taxonomy":"tx_company","embeddable":true,"href":"https:\/\/sosv.com\/wp-json\/wp\/v2\/tx_company?post=18198"},{"taxonomy":"tx_category","embeddable":true,"href":"https:\/\/sosv.com\/wp-json\/wp\/v2\/tx_category?post=18198"},{"taxonomy":"tx_trend","embeddable":true,"href":"https:\/\/sosv.com\/wp-json\/wp\/v2\/tx_trend?post=18198"},{"taxonomy":"tx_program","embeddable":true,"href":"https:\/\/sosv.com\/wp-json\/wp\/v2\/tx_program?post=18198"},{"taxonomy":"posts_type","embeddable":true,"href":"https:\/\/sosv.com\/wp-json\/wp\/v2\/posts_type?post=18198"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}